Tiago Pina Cabral, Medical Oncology Resident at CHLO,EPE, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“I am pleased to share our latest paper published in Cancers MDPI :
‘Age and Clinical Outcomes of Immune Checkpoint Inhibitor Toxicities in Portugal: A Decade of Pharmacovigilance’
Using more than 10 years of nationwide pharmacovigilance data from Portugal, we evaluated real-world safety patterns of immune checkpoint inhibitors (ICIs), with a specific focus on age.
Key findings:
- Chronological age (≥70 years) did not increase the likelihood of reporting serious ICI-related adverse events
- However, when toxicity occurred, fatal outcomes were significantly more frequent in older adults
- Toxicity phenotypes differed by age (more nervous and immune system events in ≥70 years; more hepatobiliary and hematologic events in younger patients)
- CTLA-4–containing regimens showed the most severe toxicity profiles
- Safety outcomes improved substantially over time, likely reflecting better recognition and management of irAEs
These results support continued access to immunotherapy for fit older adults, while reinforcing the need for earlier recognition, age-attuned monitoring, and rapid escalation pathways.
Grateful to my co-authors and collaborators at INFARMED.”
Title: Age and Clinical Outcomes of Immune Checkpoint Inhibitor Toxicities in Portugal: A Decade of Pharmacovigilance
Authors: Tiago Pina-Cabral, José Pereira, João Paulo-Fernandes, Márcia Silva, Mário Fontes-Sousa, Mariana Anacleto, Soraia Lobo-Martins, Ana Mirco, Helena Miranda, Ana Martins, Patrícia Cavaco
Read the Full Article on Cancers MDPI
Lissandra Dal Lago, Medical Oncologist at CHIREC Hospital Group, shared this post, adding:
“Very important real-world data on IO toxicity older adults with cancer.
Call attention to mortality rates with doublet ICIs. Highlighting older age and decreased functional reserve is a key aspect to be evaluated in CGA before treatment start! Congratulations!”
More posts about Immune Checkpoint Inhibitor.